Sign in

Martha Ha

Executive Vice President, General Counsel and Corporate Secretary at US Foods HoldingUS Foods Holding
Executive

About Martha Ha

Executive Vice President, General Counsel and Corporate Secretary at US Foods; joined in September 2023. Responsible for legal, food safety, risk management, securities and corporate governance, corporate sustainability, M&A, and ethics & compliance; named as a company proxy for the 2025 Annual Meeting and frequently signs SEC current reports . Education: JD (Loyola Chicago School of Law), BS (University of Illinois); Certified Public Accountant . Company performance context: FY2024 net sales were $37.9B (+6.4% YoY) and Adjusted EBITDA was $1.74B (+11.7% YoY), with five-year cumulative TSR at $161 (value of $100 invested in 2019) .

Past Roles

OrganizationRoleYearsStrategic Impact
US FoodsEVP, General Counsel & Corporate Secretary2023–presentLeads legal, governance, sustainability, risk, food safety, and M&A
MedtronicVP, Chief Counsel – Securities & Corporate Governance; M&A; Cardiovascular Portfolio; Chief Privacy Officer~2016–2023Led securities/corporate governance, sustainability, insurance/aviation; privacy governance; supported portfolio/M&A
DaVita HealthCare PartnersVP, Corporate Secretary & General Counsel – Corporate & International2011–2016Led corporate governance and international legal strategy
W.W. GraingerVP, Corporate Secretary & Deputy General CounselPrior to 2011Corporate governance and legal leadership at a large distributor
Baxter HealthcareVarious legal rolesPrior to GraingerLegal roles of increasing responsibility in medtech
Arthur Andersen; Chicago law firms (Bell, Boyd & Lloyd; Coffield Ungaretti & Harris; Shefsky & Froelich)Auditor; AttorneyEarly careerFoundational experience in audit and corporate law

External Roles

OrganizationRoleYearsStrategic Impact
MedtronicCo-Chair, Asian Impact Employee Network2019–2023D&I leadership and employee engagement

Fixed Compensation

  • Not disclosed for non-NEO executive officers like General Counsel. US Foods’ proxy reports detailed amounts only for Named Executive Officers (NEOs) .
  • Program architecture applies company-wide: base salary set via benchmarking; annual cash AIP based on company metrics; LTIP mix of RSUs/PRSUs for executives, with RSUs vesting over 3 years .

Performance Compensation

Annual Incentive Plan (AIP) – FY2024 design and results (company-level metrics applicable to executive officers)

MetricWeightingTargetActualPayout (unweighted)
Adjusted EBITDA ($B)70%1.7201.741114%
Distribution Cost Per Case (improvement vs FY2023)15%-$0.026-$0.1150%
IND Market Share (bps YoY change, 4Q avg)15%60 bps27 bps38%
Business Performance Factor (before safety)86%
Safety Modifier (AFR/IFR improvement)+/-10%31% improvement → +10%19% improvement+3.13%
Business Performance Factor (after safety)89%

Notes:

  • AIP caps at 200% of target; safety modifier is applied to the business performance factor .
  • The AIP framework (weights and modifier) applies to executive officers; individual payouts for non-NEOs are not disclosed .

Long-Term Incentive Plan (LTIP) – FY2024 structure (executive-wide)

  • 50% time-based RSUs (3-year ratable vesting), 50% PRSUs tied to Adjusted EBITDA growth (70%) and ROIC growth (30%), with annual targets set for each of 2024–2026 and vesting based on the simple average of yearly payouts; payout range 0–200% .
  • Change-in-control treatment: double-trigger; PRSUs vest at target if awards are not assumed or upon qualifying termination within 18 months post-CIC .

Equity Ownership & Alignment

ItemDetails
Beneficial ownership at appointmentForm 3 filed 10/2/2023 reported “No securities are beneficially owned.” (initial statement upon becoming an officer)
Stock ownership guidelines (executives)3x base salary; five years to comply; retain 50% of net shares until compliant; all executive officers were compliant or on track at FY2024 year-end
Hedging/pledgingProhibited for directors and executive officers; also prohibits short-term trades, short sales, and exchange-traded options in company stock
Proxy designation and governanceDesignated as one of the two proxies for the 2025 Annual Meeting; Corporate Secretary role indicates deep involvement in governance and investor communications
Sustainability leadershipThe Sustainability Steering Committee is led by the CFO and General Counsel; Ha is described as Sustainability Lead

Employment Terms

ProvisionExecutive-wide terms (apply to General Counsel)
Employment statusAt-will; no fixed-term employment agreement
Severance (no CIC)18 months salary continuation; fixed bonus equal to 1.5x AIP target; prorated AIP for year of termination; lump-sum COBRA premium equivalent; subject to release
Severance (CIC + qualifying termination within 18 months)Lump-sum 24 months base salary; fixed bonus equal to 2x AIP target; prorated AIP for year; lump-sum COBRA premium equivalent; double-trigger only
Equity treatment (CIC)RSUs fully vest and PRSUs vest at target if not assumed or upon qualifying termination within 18 months post-CIC
RSU/PRSU retirement/disability/deathRetirement (≥1 year post-grant): continued RSU vesting; PRSUs vest pro-rata subject to performance; death/disability: RSUs fully vest, PRSUs pro-rata
Restrictive covenantsNon-disclosure, non-competition, non-solicitation, non-interference; severance clawback for covenant violations or fraud-related restatement
ClawbackDodd-Frank compliant policy to recover erroneously awarded incentive compensation for 3 years preceding required restatement

Performance & Track Record (Company context for pay-for-performance and execution)

MetricFY 2022FY 2023FY 2024
Revenues ($)34,057,000,000*35,597,000,000*37,877,000,000*
EBITDA ($)1,016,000,000*1,438,000,000*1,562,000,000*
Net Income - (IS) ($)265,000,000*506,000,000*494,000,000*
Cash from Operations ($)765,000,000*1,140,000,000*1,174,000,000*

Values retrieved from S&P Global.*
Additional company highlights: Net sales $37.9B (+6.4%), Adjusted EBITDA $1.74B (+11.7%), Adjusted EBITDA margin expanded 22 bps, and five-year cumulative TSR reached $161 (vs. a $100 initial investment) .

Compensation Committee & Governance Signals (context for alignment)

  • AIP metrics emphasize Adjusted EBITDA, distribution productivity, and independent-restaurant market share with a safety modifier; maximum payouts capped at 200% .
  • LTIP reinstated PRSUs at 50% of mix to strengthen pay-for-performance; metrics directly tied to long-range plan (Adjusted EBITDA and ROIC growth) .
  • Anti-hedging/pledging policy and ownership requirements drive alignment; double-trigger CIC severance and no option repricing/gross-ups reflect shareholder-friendly practices .
  • Peer group covers food distributors and scale distributors/retailers; compensation benchmarking generally targets competitive market medians .
  • 2024 Say-on-Pay received 94% approval, indicating broad investor support .

Risk Indicators & Red Flags

  • Related party transactions: none above $120,000 in FY2024 except a disclosed stock repurchase agreement with a >5% holder (Sagamore Master VIII) for 4,000,000 shares at $52.2847; not involving executives .
  • Anti-hedging and anti-pledging policies materially reduce alignment risks; clawback policy strengthens accountability .
  • No disclosure of personal hedging/pledging for Ha; Form 3 at appointment showed no beneficial holdings .

Investment Implications

  • Alignment: Strong governance architecture—ownership guidelines (3x salary), hedging/pledging prohibitions, and clawbacks—reduces misalignment risk for senior executives, including the General Counsel .
  • Retention and CIC: Double-trigger severance and equity treatment balance retention with shareholder protections; restrictive covenants and clawback add deterrence against adverse behavior .
  • Execution context: Company-level AIP/LTIP metrics (Adjusted EBITDA, ROIC, cost productivity, market share, safety) directly tie executive rewards to operational and financial outcomes under the long-range plan—supporting pay-for-performance discipline .
  • Ownership signal: Lack of disclosed personal holdings at appointment (Form 3) is neutral given guideline compliance expectations; monitoring future Forms 4 would refine “skin-in-the-game” analysis .